Skip to main content

Table 4 Follow up of patients injected with placebo

From: Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

Patient number Age (years) Date of surgery Type of treatment Tumour size (cm) Total nodes Metastatic nodes Grade Date of first injection Side effects Recurrence Last follow up Follow up (months)
17 62 11/12/97 Total mast + tam 2.5 27 1 II 28/01/98 Mild skin redness - 14/06/05 99
18 54 14/12/97 Partial mast + RT + tam 2.0 20 1 II 10/01/98 - Local, 14/07/99 14/06/05 99
19 55 16/12/97 Partial mast + RT + tam 1.5 17 1 II 06/05/98 - - 14/06/05 99
20 60 23/12/97 Partial mast + RT + tam 2.3 24 2 II 13/12/97 - - 16/06/05 99
21 62 20/01/98 Total mast + tam 2.4 27 2 II 13/03/98 - - 16/06/05 98
22 61 13/03/98 Total mast + tam 1.8 23 2 I 29/04/98 - - 17/06/05 97
23 62 01/04/98 Partial mast + RT + tam 1.5 12 1 II 08/07/98 Mild skin redness - 17/06/05 96
24 54 29/04/98 Partial mast + RT + tam 0.5 17 1 III 22/07/98 Mild skin redness - 21/06/05 96
25 58 10/11/98 Total mast + tam 2.2 21 3 II 30/01/98 - Bone, 13/11/00 Death 10/11/03  
26 51 17/02/99 Partial mast + RT + tam 2.0 11 1 II 10/03/99 - Bone, 28/09/00 21/06/05 86
27 71 10/06/99 Total mast + tam 3.2 26 1 II 01/07/99 - - 23/06/05 82
28 70 30/06/99 Partial mast + RT + tam 2.0 20 3 II 13/07/99 - - 23/06/05 82
29 54 02/12/99 Partial mast + RT + tam 2.5 12 1 II 10/01/00 - - 24/06/05 76
30 81 08/12/99 Total mast + tam 2.5 14 1 III 10/01/00 - - 27/06/05 75
31 58 24/02/00 Partial mast + RT + tam 2.0 13 3 II 20/03/00 Mild skin redness Liver, 16/11/00 Death 2002  
  1. mast, mastectomy; M-FP, oxidized mannan conjugated to MUC1 fusion protein; RT, radiotherapy; tam, tamoxifen.